Stockreport

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024 [Yahoo! Finance]

Vaxxinity, Inc.  (VAXX) 
PDF LISBON, Portugal, March 07, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ: VAXX ), a U.S. company pioneering the development of a new class of medicines, announced p [Read more]